717 related articles for article (PubMed ID: 9330608)
21. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
[TBL] [Abstract][Full Text] [Related]
22. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
Miki T; Nonomura N; Takaha N; Nishimura K; Kojima Y; Sawada M; Okuyama A
Int J Urol; 1998 Jul; 5(4):370-3. PubMed ID: 9712447
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
[TBL] [Abstract][Full Text] [Related]
25. Biological impact and therapeutic potential of a novel camptothecin derivative (FLQY2) in pancreatic cancer through inactivation of the PDK1/AKT/mTOR pathway.
Wang W; Xiong H; Li L; Hu X; Zhuang W; Li J; Sun X; Yu Y; Yu Y; Guo Y; Wang Y; Wang R; Wang H; Li Q
Bioorg Chem; 2024 Jul; 148():107436. PubMed ID: 38735265
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Miki T; Sawada M; Nonomura N; Kojima Y; Okuyama A; Maeda O; Saiki S; Kotake T
Eur Urol; 1997; 31(1):92-6. PubMed ID: 9032542
[TBL] [Abstract][Full Text] [Related]
27. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
28. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R
Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
31. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
32. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
33. Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16.
Nagai S; Yamauchi M; Satta T; Kodera Y; Kondou K; Akiyaya S; Ito K; Takagi H
J Surg Oncol; 1993 Dec; 54(4):211-5. PubMed ID: 8255079
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E
Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672
[TBL] [Abstract][Full Text] [Related]
37. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Nagai S; Yamauchi M; Andoh T; Nishizawa M; Satta T; Kodera Y; Kondou K; Akiyama S; Ito K; Takagi H
J Surg Oncol; 1995 Jun; 59(2):116-24. PubMed ID: 7776652
[TBL] [Abstract][Full Text] [Related]
39. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.
Zou Y; Wu QP; Tansey W; Chow D; Hung MC; Charnsangavej C; Wallace S; Li C
Int J Oncol; 2001 Feb; 18(2):331-6. PubMed ID: 11172600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
